【作者】 罗盛； 胡旭东； 沈志坚； 张君丽； 孙岚； 陈怡；

【Author】 LUO Sheng HU Xudong SHEN Zhijian ZHANG Junli SUN Lan CHEN Yi Department of Hematology The First Affiliated Hospital of Wcnzhou Medical College Wenzhou 325000 China

【机构】 浙江省温州医学院附属第一医院血液内科；

【摘要】 目的:复发或难治性非霍奇金淋巴瘤目前尚无标准的解救化疗方案,EPOCH、MINE、DHAP 和 DICE 等常见的解救治疗方案缓解率约为30%～70%。本文旨在观察 ESHAP 方案作为解救化疗方案治疗复发或难治性侵袭性 NHL 的疗效和安全性。方法:选取38例复发或难治性侵袭性 NHL 患者, 使用 ESHAP 作为解救方案进行化疗。结果:38例患者各接受了2～6个周期该方案化疗,总的客观有效率为55.3%,完全缓解率26.3%;主要不良反应为骨髓抑制伴感染,均可耐受。结论:ESHAP 方案是治疗复发或难治性侵袭性 NHL 安全有效的解救方案之一。更多还原

【Abstract】 Objective:There’s no standard salvage regimen for relapsed or refractory non-Hodgkin’s lymphoma(NHL) yet.So far,the responsive rates(RR)of NHL patients received common salvage regimens,such as EPOCH,MINE,DHAP and DICE,are 30%-70%.The study was to evaluate the efficacy and safety of ESHAP regimen,as a salvage regimen,in treating patients with relapsed or refractory aggressive NHL.Methods:38 patients with relapsed or refractory aggressive NHL were selected to be therapied by ESHAP regimen.Results:The 38 patients received ESHAP regimen with a range of 2-6cycles.The total RR was 55.3% with complete response(CR)rate of 26.3%.The major toxicity was myelosuppression with infection,which was tolerable.Conclusion:ESHAP regimen is one of safe and effective salvage regimere for the patients with relapsed or refractory aggressive NHL.更多还原